Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer (2020)
Attributed to:
Integrating innovative technologies for genotyping and phenotyping in stratified medicine
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.18632/oncotarget.27681
PubMed Identifier: 32922659
Publication URI: http://europepmc.org/abstract/MED/32922659
Type: Journal Article/Review
Parent Publication: Oncotarget
Issue: 34
ISSN: 1949-2553